Principal Financial Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-12,969
Closed -$233K 2388
2020
Q2
$233K Buy
12,969
+1,253
+11% +$17.4K ﹤0.01% 2146
2020
Q1
$84K Sell
11,716
-9,350
-44% -$117K ﹤0.01% 2130
2019
Q4
$503K Buy
21,066
+564
+3% +$15.6K ﹤0.01% 1946
2019
Q3
$550K Buy
20,502
+1,946
+10% +$54.6K ﹤0.01% 1927
2019
Q2
$504K Sell
18,556
-156
-0.8% -$4.89K ﹤0.01% 1959
2019
Q1
$649K Buy
+18,712
New +$540K ﹤0.01% 1888
2018
Q4
Sell
-22,282
Closed -$593K 2357
2018
Q3
$593K Buy
22,282
+3,070
+16% +$100K ﹤0.01% 1933
2018
Q2
$726K Buy
19,212
+1,054
+6% +$40.3K ﹤0.01% 1897
2018
Q1
$593K Sell
18,158
-36,741
-67% -$1.61M ﹤0.01% 1916
2017
Q4
$2.67M Sell
54,899
-7,230
-12% -$366K ﹤0.01% 1713
2017
Q3
$3.36M Sell
62,129
-564
-0.9% -$33.1K ﹤0.01% 1661
2017
Q2
$3.52M Buy
62,693
+371
+0.6% +$14.9K ﹤0.01% 1646
2017
Q1
$2.44M Buy
62,322
+202
+0.3% +$6.43K ﹤0.01% 1702
2016
Q4
$1.39M Buy
62,120
+9,657
+18% +$189K ﹤0.01% 1767
2016
Q3
$1.19M Buy
52,463
+43,814
+507% +$1.03M ﹤0.01% 1746
2016
Q2
$204K Buy
+8,649
New +$214K ﹤0.01% 2026
2016
Q1
Sell
-7,961
Closed -$410K 2214
2015
Q4
$410K Hold
7,961
﹤0.01% 1883
2015
Q3
$339K Buy
7,961
+1,011
+15% +$48.8K ﹤0.01% 1923
2015
Q2
$317K Buy
6,950
+138
+2% +$5.55K ﹤0.01% 1941
2015
Q1
$259K Buy
+6,812
New +$234K ﹤0.01% 1965

Principal Financial Group's PTLA Position: Q3 2020 in Review

Principal Financial Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 12,969 shares — an estimated $233K sold.

Principal Financial Group first reported a position in PTLA in Q1 2015 and held it in 20 quarters. The position peaked at $3.52M in Q2 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Principal Financial Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Principal Financial Group sold 12,969 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $233K.
  • Principal Financial Group first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 20 quarters.
  • Principal Financial Group's Portola Pharmaceuticals, Inc. position peaked at $3.52M in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Principal Financial Group's 13F filing for Q3 2020, filed 6 Nov 2020.